Sofdra’s Strong Early Launch, High Refill Momentum, and Expanding Market Support Buy Rating on Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a A$2.00 price target.

Joseph Pantginis has given his Buy rating due to a combination of factors tied to Sofdra’s robust early launch performance and growth trajectory. He highlights that quarterly net revenue is rising at a strong pace, supported by a meaningful increase in total prescriptions as the company expands its U.S. sales footprint to 50 territories. The rapidly growing prescriber base, together with refill rates substantially above typical dermatology benchmarks, points to strong product adoption, high patient adherence, and durable demand. He also notes that the Botanix Fulfillment Platform, which routes prescriptions outside traditional wholesaler channels, is playing a key role in driving this momentum and is expected to further enhance revenue scalability.
In addition, Pantginis emphasizes positive trends in Sofdra’s gross-to-net dynamics, which are moving toward management’s targeted range and should support improving profitability as volume builds. Management’s commentary that refills, rather than just new starts, are the primary growth engine reinforces the view of a recurring revenue stream as coverage stabilizes and patient “stickiness” increases. Combined with a large addressable market in primary axillary hyperhidrosis and his projection of peak Sofdra sales approaching $825 million, these metrics underpin his confidence in Botanix’s long-term value creation potential. Together, these operational, financial, and market drivers form the basis for maintaining a Buy recommendation on Botanix Pharmaceuticals Limited.

In another report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a A$0.24 price target.